학술논문
Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)
Document Type
Article
Author
Source
In: European Journal of Cancer , 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (European Journal of Cancer, October 2022, 174:S36)
Subject
Language
English
ISSN
18790852
09598049
09598049